Related Experiment Videos
Extraocular retinoblastoma: a 13-year experience
Célia Beatriz Gianotti Antoneli1, Flávio Steinhorst, Karina de Cássia Braga Ribeiro
1Department of Pediatric Oncology, Hospital do Câncer, A. C. Camargo, Centro de Tratamento e Pesquisa, São Paulo, Brazil. cantonelli@terra.com.br
Cancer
|September 16, 2003
Summary
Adding ifosfamide and etoposide did not improve survival for extraocular retinoblastoma. Aggressive treatments remain ineffective for advanced disease, necessitating further research into optimal strategies.
Area of Science:
- Pediatric Oncology
- Ophthalmology
- Cancer Treatment
Background:
- Retinoblastoma is a pediatric eye cancer.
- Extraocular retinoblastoma indicates advanced disease.
- Understanding clinical and epidemiologic characteristics is crucial.
Purpose of the Study:
- To evaluate two different treatment regimens for extraocular retinoblastoma.
- To describe the clinical and epidemiologic features of affected patients.
Main Methods:
- Retrospective analysis of 83 patients with extraocular retinoblastoma (Childrens Cancer Group classification).
- Analysis of patient demographics, tumor characteristics, and treatment protocols.
- Comparison of two chemotherapy regimens: (1) cisplatin, teniposide, vincristine, doxorubicin, cyclophosphamide; (2) cisplatin, teniposide, ifosfamide, etoposide.
Main Results:
- The mean age was 32.9 months, with a mean lag time of 10.5 months.
- 83.1% of patients had locally advanced tumors (Class I-III).
- 5-year overall survival rates were similar between the two treatment periods (55.1% vs. 59.4%).
Conclusions:
- The addition of ifosfamide and etoposide did not enhance survival for extraocular retinoblastoma.
- Central nervous system dissemination or metastatic disease remains incurable.
- Multicenter trials are needed to determine optimal treatment strategies for advanced cases.